MML Investors Services
IOVA icon

MML Investors Services’s Iovance Biotherapeutics IOVA Stock Holding History

MML Investors Services’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
107,785
+12
+0% +$46 ﹤0.01% 2546
2026
Q1 		$378K Sell
107,773
-4,075
-4% -$13K ﹤0.01% 2401
2025
Q4 		$305K Buy
+111,848
New +$259K ﹤0.01% 2614

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MML Investors Services's IOVA Position: Q2 2026 in Review

MML Investors Services increased its Iovance Biotherapeutics (IOVA) stake by 0.01% in Q2 2026, buying an estimated $46 and bringing the position to 107,785 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

MML Investors Services first reported a position in IOVA in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • MML Investors Services held 107,785 shares of Iovance Biotherapeutics worth $448K as of Q2 2026.
  • MML Investors Services bought 12 Iovance Biotherapeutics shares in Q2 2026, an estimated $46.
  • Iovance Biotherapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #2546 holding.
  • MML Investors Services first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.